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Abstract
Background: The incidence of cancer in patients with neurological diseases, who have been treated with LiCl, is
below average. LiCl is a well-established inhibitor of Glycogen synthase kinase-3, a kinase that controls several
cellular processes, among which is the degradation of the tumour suppressor protein p53. We therefore wondered
whether LiCl induces p53-dependent cell death in cancer cell lines and experimental tumours.
Results: Here we show that LiCl induces apoptosis of tumour cells both in vitro and in vivo. Cell death was
accompanied by cleavage of PARP and Caspases-3, -8 and -10. LiCl-induced cell death was not dependent on p53,
but was augmented by its presence. Treatment of tumour cells with LiCl strongly increased TNF-a and FasL
expression. Inhibition of TNF-a induction using siRNA or inhibition of FasL binding to its receptor by the Nok-1
antibody potently reduced LiCl-dependent cleavage of Caspase-3 and increased cell survival. Treatment of
xenografted rats with LiCl strongly reduced tumour growth.
Conclusions: Induction of cell death by LiCl supports the notion that GSK-3 may represent a promising target for
cancer therapy. LiCl-induced cell death is largely independent of p53 and mediated by the release of TNF-a and
FasL.
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Background
Tumour necrosis factor alpha (TNF-a) is a cytokine that
is mainly secreted by activated macrophages, although
other cell types can also produce this protein in
response to certain stimuli [1]. After binding to its cor-
responding transmembrane receptor, tumour necrosis
factor receptor (TNF-R), TNF-a exerts cytostatic and
cytotoxic activity against a wide range of human and
murine cell lines [2,3]. Binding of TNF-a to its receptor
induces receptor trimerisation on the cell surface and
formation of a death-inducing signalling complex
(DISC) at the cytoplasmic tail of TNF-R, leading to acti-
vation of Caspase-8 and induction of apoptosis [4].
Similar to TNF-a, FasL stimulates the formation of a
DISC upon binding to its receptor (reviewed in: [5]) and
induces cell death.
LiCl (lithium chloride), the lithium salt of hydrochloric
acid is an important therapeutic agent for the treatment
of patients suffering from bipolar disorder and depres-
sion [6]. Its main cellular target is Glycogen synthase
kinase-3 (GSK-3). At least at physiological doses, LiCl
has no effect on other protein kinases [7]. GSK-3 is a
serine/threonine kinase that was initially identified as a
regulator of glycogen synthase [8,9]. Mammals possess
two isoforms of GSK-3 (a and b) [10]. Unlike most
other protein kinases, GSK-3 is constitutively active in
resting cells. Exposure to insulin, epidermal growth fac-
tor, ionizing radiation or phorbol ester, however, leads
to rapid inactivation of GSK-3, which constitutes a
determinant of embryonic development and cell fate
[11-14]. Apart from LiCl, GSK-3 is efficiently inhibited
by paullones, amongst which alsterpaullone is the most
specific derivative [15].
GSK-3 phosphorylates several cellular substrates,
including transcription factors such as c-Jun, c-Myb,
CREB (cAMP response element binding protein) and
Mdm2 [11,16-19]. Mdm2 is a ubiquitin ligase for the
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p53 tumour suppressor protein and some other targets
[20]. GSK-3 phosphorylates the Mdm2 protein in its
central domain and this phosphorylation is essential for
Mdm2-mediated degradation of the p53 protein [11].
Accordingly, inhibition of GSK-3 leads to the accumula-
tion of p53 and transcription of its target genes [11].
Since p53 is a protein with strong anti-proliferative
and pro-apoptotic activities [21], we speculated that
inhibition of GSK-3 may prevent cell proliferation and
induce cell death in cells with wild type p53. Here we
show that LiCl is a potent inducer of apoptosis both
in vitro and in vivo. Although the presence of p53
slightly modifies the response, this tumour suppressor
protein is not required for induction of cell death by
LiCl. Moreover, we report that a major way in which
LiCl induces apoptosis is by inducing autocrine produc-
tion of TNF-a and FasL, thereby activating the extrinsic
apoptotic pathway.
Results
LiCl and alsterpaullone prevent proliferation of tumour
cells
Previous investigations showed that inhibition of GSK-3
leads to the accumulation and activation of p53 [11,22],
a tumour suppressor protein that induces cell cycle
arrest and apoptosis. With this in mind, we investigated
the consequence of GSK-3 inhibition on the prolifera-
tion of tumour cells.
We incubated the human colon carcinoma cell line
HCT116, and the two human osteosarcoma cell lines
U2OS and SaOs-2 as well as mouse embryonic fibro-
blasts (MEFs) with increasing doses of LiCl and alster-
paullone and determined relative cell proliferation by
MTT assay. Since we were particularly interested
whether an eventual induction of cell death would
require the p53 protein, we used HCT116 and MEF
wild type cell lines and corresponding cell lines with a
genetic deletion of p53. In addition, we employed the
two osteosarcoma cell lines U2OS (p53 wild type) and
SaOs-2 (p53-deficient) which differ in their p53 status.
In Additional file 1, Figure S1, we show that p53 is only
expressed in the wild type counterparts of HCT116 and
MEF as well as in U2OS but not in the derivatives with
deleted p53 alleles or in SaOS-2. As shown in Figure 1A
I-VI, treatment of the different cell lines with LiCl
strongly reduced cell proliferation in a dose dependent
manner. Similar results were obtained with HaCaT,
RKO and Hela tk- cell lines (data not shown). For MEF
and HCT116 cells, we observed a decrease in the num-
ber of viable cells starting from about 3 mM LiCl. The
half-lethal dose (LD50) for both cell lines was between
10 and 30 mM LiCl. SaOs-2 and U2OS cells required
higher doses. Here, a clear decrease in the relative
number of viable cells was only reached beyond 10 mM.
The LD50 for U2OS was between 10 and 30 mM and
for SaOs-2 between 30 and 60 mM. In all cases, we
observed a slightly higher sensitivity of p53-replete cells
than of p53-deficient cells, particularly at lower doses
(Figure 1A I-VI). When we treated U2OS and HCT116
cells with the p53 inhibitor pifithrin-a [23], we also
observed a slightly reduced sensitivity (Additional file 2,
Figure S2A), signifying a contribution of p53 to LiCl-
mediated cell death. However, when we knocked p53
down by siRNA, we found at best a slightly increased
survival in the presence of p53 (Additional file 2, Figure
S2B), supporting the notion that p53 is not an impor-
tant mediator of LiCl-induced cell death.
When we investigated the colony forming ability of
HCT116 cells, we observed a slightly higher sensitivity
for LiCl than found with the MTT assay. Here, prolif-
eration of p53-replete cells was already slightly reduced
at 1 mM LiCl, while p53-deficient cells required at least
3 mM LiCl for inhibition of colony forming ability
(Additional file 3, Figure S2C).
To investigate whether the reduction in proliferation
in response to LiCl might be due to inhibition of GSK-
3, we repeated these experiments with another inhibitor
of GSK-3, alsterpaullone. Here, proliferation of HCT116
was already reduced at a dose of 0.3 μM alsterpaullone
while the other cell lines required at least 1 μM of the
drug for growth suppression (Figure 1A I-VI). LD50s
were at about 3 μM for MEFs, between 0.6 and 1 μM
for HCT116 and between 1 and 3 μM for the two osteo-
sarcoma cell lines.
We next examined cell proliferation after treating the
cells for several days with LiCl or alsterpaullone at
approximately the LD50 dose. For MEFs and HCT116
cells, we saw a constant increase in cell number with
time. This increase was, though, much weaker in the
presence of LiCl or alsterpaullone (Figure 1B I-IV). For
U2OS cells, we observed a slightly different picture.
Here we found that after an initial increase in cell num-
ber, even in the presence of LiCl or alsterpaullone, the
number of cells remained more or less constant (alster-
paullone), or even declined (LiCl; Figure 1B V). For
SaOs-2, we observed a strong reduction in proliferation
at initial time points, but at later time points inhibition
of proliferation ceased (Figure 1B VI).
LiCl induces cell death in p53-positive and p53-negative
cells
We next investigated whether the decrease in prolifera-
tion after treatment of tumour cells with LiCl was due
to the induction of cell death. By performing FACS-ana-
lysis, we observed both in p53-positive and in p53-nega-
tive HCT116 cell lines a clear increase in the sub-G1
peak starting at 16h after LiCl addition and increasing
thereafter. This increase in the sub-G1 peak was more
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Figure 1 Treatment of cells with LiCl and alsterpaullone reduces cell proliferation. (A.I-A.VI) Wild type (wt) and p53-deficient mouse
embryonic fibroblasts (MEF) and HCT116 cells as well as U2OS and SaOs-2 cells were plated in 96-well plates at a density of 1 × 103 cells per well.
24 hours after plating, LiCl and alsterpaullone (Alster) were added at the indicated concentrations. 72 hours after drug addition, the relative number
of viable cells was determined by MTT-assay. Mean values and standard deviations of three independent experiments were calculated and plotted.
The relative number of cells in the absence of drug was set to 100% (D: DMSO control). (B.I-B.VI) Wild type (wt) and p53-deficient mouse
embryonic fibroblasts (MEF) and HCT116 cells as well as U2OS and SaOs2 cells were plated in 24-well plates at a density of 5 × 103 cells per well.
24 hours after plating, LiCl and alsterpaullone (Alster) were added at a concentration approximating LD50 as determined by the MTT assay (A.I-A.VI).
U2OS cells and MEFs received a final concentration of 17.5 mM LiCl or 1.5 μM alsterpaullone, SaOs-2 cells were treated with 25 mM LiCl or with
1.5 μM alsterpaullone and HCT116 cells received 12.5 mM LiCl and 0.6 μM alsterpaullone. Cells were counted at the indicated days. Mean values
and standard deviations of three independent experiments were calculated and plotted.
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prominent in the p53-proficent cell line (Figure 2A). At
the same time, we observed a significant decrease in G1
and S-phase cells and an increase in G2 cells, which was
transient in the case of p53-replete cells and persistent
in the case of p53-deficient cells (Figure 2A). Interest-
ingly, although HCT116-p53-replete and p53-deficient
cells both induced cell death in response to LiCl to a
similar extent, they responded somewhat differently to
the death-inducing stimulus. Both cell lines differed sig-
nificantly regarding the alterations in G1-, S-phase and
G2-cells. Annexin V/PI-staining revealed that there is
also an increase in the number of necrotic cells in
response to LiCl, although the values only reached sta-
tistical significance in the case of p53-negative cells at
36h after LiCl addition (Figure 2B).
Cell death by apoptosis is characterized by cleavage of
PARP and Caspase-3, and by DNA fragmentation
[24,25]. Consistent with the data from the FACS analy-
sis, which indicated already that LiCl induces apoptosis,
we observed a decrease in the 116 kDa form and an
increase in the 86 kDa form of PARP after addition of
LiCl in a time and dose-dependent manner (Figure 2C;
Additional file 3, Figure S3A). In HCT116 wild type
cells, the 86 kDa form of PARP was already detectable
at twenty-four hours after LiCl treatment and most pro-
minent at thirty-six hours post LiCl addition. Thereafter,
both the 116 kDa and the 86 kDa form of PARP
declined. Twelve hours after the initial signs of PARP
cleavage, cleavage of Caspase-3 could be observed
(Figure 2D; Additional file 3, Figure S3A). For cells defi-
cient in p53, cleavage of PARP and Caspase-3 was much
weaker and could only be observed at later time points,
for example cleavage of PARP after 36 hours, and clea-
vage of Caspase-3 after 48 hours Figure 2C, D). This
cleavage of PARP and Caspase-3 was clearly detectable
when HCT116 cells had received a dose of 30 mM LiCl.
P53-deficient cells showed PARP cleavage after a dose
of 30 mM LiCl, while cleavage of Caspase-3 was already
visible after a dose of 15 mM LiCl (Additional file 3,
Figure S3A). However, despite this indication that p53
might be important for Caspase-3 cleavage after LiCl-
treatment, we did not see reduced cleavage of Caspase-3
when we inhibited the transactivation function of p53
by pifithrin-a [23], the mitochondrial activities of p53
by pifithrin-μ [26], nor both activities by addition of
both drugs (Additional file 3, Figure S3B). Downregula-
tion of p53 by siRNA also had no strong impact on
cleavage of Caspase-3 after treatment of U2OS cells
with LiCl (Additional file 3, Figure S3C) Consistent with
these observations, we found that chromosomal DNA
was cleaved in p53-positive and p53-negative HCT116
cells. DNA fragmentation could already be observed at
sixteen hours after LiCl addition and increased during
the following eight hours (Figure 2E, F). In the absence
of p53, DNA fragmentation was somewhat reduced,
further supporting a modifying but facultative role of
p53 for induction of cell death by LiCl.
Inhibition of GSK-3 induces apoptosis in tumour cells
The similar outcome after treatment of the tumour cell
lines with the two inhibitors of GSK-3, LiCl and alster-
paullone suggested that the growth suppressive activities
of LiCl in tumour cells may be due to inhibition of
GSK-3. To substantiate this notion we determined
whether downregulation of GSK-3a, GSK-3b or both
isoforms by siRNA is sufficient to induce apoptosis as
measured by Caspase-3 cleavage. As shown in Figure 3,
siRNAs targeted against the two GSK-3 isoforms led to
a strong reduction in GSK-3a and GSK-3b protein
levels. At the same time, Caspase-3 cleavage was
strongly increased after downregulation of GSK-3a, and
this cleavage of Caspase-3 was further enhanced after
downregulation of both GSK-3 isoforms (Figure 3).
Transfection with a non-related control siRNA did not
cause cleavage of Caspase-3, demonstrating the specifi-
city of the effect for GSK-3 siRNAs
LiCl induces cell death by the extrinsic apoptosis pathway
Apoptosis can be initiated by different signalling cascades
(reviewed in: [27]). The most frequently used ones are the
intrinsic pathway that is characterized by release of cyto-
chrom C from mitochondria and activation of Caspase-9
and the extrinsic pathway that activates Caspase-8 and/or
Caspase-10. To investigate which pathway is activated by
LiCl-dependent cell death, we determined the release of
cytochrome C. However, we failed to observe a significant
increase in the amount of cytochrome C in the cytoplasm
of LiCl-treated cells (Additional file 4, Figure S4). Likewise,
we observed minor activation of Caspase-9, and only in
some cell lines (data not shown). In contrast, Caspase-8
was strongly activated in p53 wild type cells, and to a lesser
degree in HCT-116 cells with a genetic deletion of the p53
gene (Figure 4A). Similarly, Caspase-10 and in particular
Caspase-10c became cleaved after treatment of cells with
LiCl in a time and dose dependent manner (Figure 4B;
Additional file 3, Figure S3A).
Activation of Caspase-8 and -10 and absence of cyto-
chrome C release strongly suggested that treatment of
cells with LiCl initiated the extrinsic apoptosis pathway.
This pathway is commonly activated by binding of solu-
ble ligands to death receptors (reviewed in [28]). We
therefore speculated that treatment of cells with LiCl
leads to the release of a soluble factor that binds to
death receptors. To test this notion, we transferred con-
ditioned medium from LiCl-treated cells to untreated
cells and investigated initiation of cell death by deter-
mining Caspase-3 cleavage. Indeed, similar to cells that
had received LiCl, cells that had received conditioned
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Figure 2 LiCl induces cell death in p53-replete and p53-deficient cells. (A) p53-positive and negative HCT116 cells were treated with 50
mM LiCl. Cells were fixed after 0, 16, 24 and 48 hours, stained with Draq5 and subjected to FACS analysis. Relative numbers of apoptotic cells
and of cells in G1-, S- and G2-phase were determined. Mean values and standard deviations of three independent experiments were calculated
and plotted. Statistical analysis was performed for alterations in the cell cycle and for induction of apoptosis in comparison to mock-treated cells
(*: P < 0.05; **: P < 0.01; ***: P < 0.001). (B) p53-positive and negative HCT116 cells were treated with 50 mM LiCl. for 0, 16, 24 and 48 hours.
Cells were stained with PI and FITC-coupled Annexin V, subjected to FACS analysis and relative numbers of apoptotic, necrotic and vital cells
were determined. Mean values and standard deviations of three independent experiments were calculated and plotted. Statistical analysis was
performed for alterations in the number of apoptotic, necrotic and vital cells in comparison to mock-treated cells (*: P < 0.05; **: P < 0.01). (C)
HCT116 wild type and HCT116 p53-/- cells were incubated with 50 mM LiCl for the indicated time. Cell lysates were prepared and 50 μg of
protein were separated on a 10% SDS-PAGE gel. Proteins were transferred onto a PVDF membrane and probed with an antibody directed
against PARP, and against PCNA for loading control. (D) HCT116 wild type and HCT116 p53-/- cells were incubated with 50 mM LiCl for the
indicated time. Cell lysates were prepared and 50 μg of protein were separated on a 15% SDS-PAGE gel. Proteins were transferred onto a PVDF
membrane and probed with an antibody directed against Caspase-3, and against PCNA for loading control. (E) HCT116 wild type and HCT116
p53-/- cells were incubated for the indicated times with 50 mM LiCl. Fragmented DNA was isolated and separated on a 1.4% agarose gel. (F)
HCT116 wild type and HCT116 p53-/- cells were incubated for the indicated times with 50 mM LiCl. The relative amount of apoptosis was
determined using the Cell Death ELISA Plus kit (Roche). Mean values and standard deviation of three independent experiments were calculated
and plotted. The readings for untreated cells were set to 1. Statistical analysis was performed for alterations in the number of apoptotic, necrotic
and vital cells in comparison to mock-treated cells (*: P < 0.05).
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medium from LiCl-treated cells also showed cleavage of
Caspase-3 (Figure 5A). This initiation of cell death by
conditioned medium was specific to LiCl-treated cells
as, for example, UVC-treated cells, which also showed
cleavage of Caspase-3, did not secrete a Caspase-3-acti-
vating factor into the culture medium (Figure 5B).
In order to identify the secreted factor, we precipitated
the proteins in the cell culture supernatant of LiCl-trea-
ted and of non-treated cells, separated these proteins on
a SDS-PAGE gel and stained the gel. We specifically
and repeatedly observed a protein band of the size of
about 17 kDa in LiCl treated cells at 36 hours after LiCl
addition that was absent in the non-treated control or
in cells treated with the same dose of LiCl, but har-
vested at sixteen hours after LiCl addition (Figure 6A.I).
Sequencing of this protein revealed it to be TNF-a
(Figure 6A.II). Furthermore, a protein of about 17 kD
was specifically recognized by an anti-TNF-a antibody
in the supernatant of LiCl-treated U2OS cells, but not
in control cells (Figure 6A.III). Moreover, rats that had
received a daily dose of LiCl for three to four weeks had
higher levels of TNF-a in their serum than vehicle-
treated controls (Figure 6A.IV).
To further support the notion that TNF-a expression
is induced by LiCl, we determined TNF-a RNA levels in
LiCl-treated and untreated cells. As shown in Figure 6B
we observed a strong dose- and time-dependent increase
in TNF-a RNA after LiCl treatment. This increase in
TNF-a RNA was observed for both p53-positive (U2OS)
and p53-negative (H1299) cells (Figure 6B.II).
TNF-a is a potent inducer of cell death in both U2OS
and HCT116 cells (Additional file 5, Figure S5A). To deter-
mine whether TNF-a is required for LiCl-induced cell
death, we knocked down TNF-a in U2OS and HCT116
cells prior to the addition of LiCl, then harvested the cells
thirty-six hours after LiCl addition and determined Cas-
pase-3 cleavage. Most importantly, downregulation of
TNF-a by siRNA reduced Caspase-3 cleavage after LiCl-
treatment by about 50% (Figure 6C.I and II; Additional file
5, Figure S5B) and reduced TNF-a RNA induction after
treatment of the cells with LiCl by more than 60% (Figure
6C.III). Furthermore, transfection of U2OS cells with TNF-
a siRNA strongly increased the number of cells that sur-
vived a 50 mM LiCl treatment (Figure 6D). In summary,
Figure 3 Downregulation of GSK-3 leads to Caspase-3
activation. U2OS cells were transfected with siRNA directed against
GSK-3a, GSK-3b or both. 72 hours after transfection, cells were
harvested and probed for GSK-3a and GSK-3b expression and for
cleaved Caspase-3 by Western Blotting. Hybridisation with an
antibody targeted against PCNA served as loading control.
Figure 4 LiCl activates the extrinsic apoptosis pathway. HCT116
wild type and HCT116 p53-/- cells were incubated with 50 mM LiCl
for the indicated time. (A.I) Cell lysates were prepared and 50 μg of
protein were separated on a 10% SDS-PAGE gel. Proteins were
transferred onto a PVDF membrane and probed with an antibody
directed against Caspase-8, and against PCNA for loading control.
(A.II) Cell lysates were prepared and the activity of Caspase-8 was
determined with the Caspase-8 activity assay (Clonetech). (B) Cells
were lysed and 50 μg of protein were separated on a 10% SDS-
PAGE gel. Proteins were transferred onto a PVDF membrane and
probed with an antibody directed against Caspase-10, and against
PCNA for loading control.
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these data strongly support the notion that TNF-a is an
important mediator of apoptosis induction by LiCl.
Beside TNF-a, we also determined alterations in FasL
expression, another protein that is able to form a DISC
complex and to induce apoptosis by the extrinsic path-
way (reviewed in: [5]. We found that FasL RNA was
also strongly induced by LiCl (Figure 7A, B), albeit not
so robustly as the induction of TNF-a RNA (Figure 6B).
When we inhibited binding of FasL to its receptor by
pre-incubation of LiCl-treated cells with the anti-FasL
antibody Nok-1, cleavage of Caspase-3 was strongly
reduced (Figure 7C; Additional file 5, Figure S5C) and
cell survival was reproducibly upregulated (Figure 7D).
Moreover, when we combined downregulation of TNF-a
and blocking of FasL/Fas interaction, we observed an
even greater reduction in Caspase-3 cleavage (Figure 7C;
Additional file 5, Figure S5C) and an additive effect on
cell survival (Figure 7D), clearly implicating both TNF-a
and FasL as mediators of LiCl-induced cell death.
Regulation of apoptosis by pro-and anti-apoptotic factors
after LiCl treatment
To investigate the regulation of pro- and anti-apoptotic
proteins that might be involved in the induction of
apoptosis, we determined the amount of Survivin, Bcl-
XL, Bid, XIAP and Bax proteins, and determined phos-
phorylation of extracellular signal-regulated kinase
(ERK) after LiCl treatment of tumour cells. To deter-
mine whether any of these pro- and anti-apoptotic pro-
teins are regulated by treatment of cells with LiCl, we
added LiCl to the cell culture and harvested the cells at
various time points. Surprisingly, the anti-apoptotic pro-
tein Survivin was induced by LiCl, although LiCl is
clearly a potent inducer of cell death. Starting from six-
teen hours after LiCl addition, we observed a significant
increase in the amount of Survivin that was further
increased up to thirty-six hours both in HCT116 wild
type and p53-deficient cells (Figure 8A). This increase
in the amount of Survivin was already evident from a
dose of 15 mM LiCl on, yet decreased at higher doses
in p53 wild type cells. In p53-deficient cells, we also
observed an increase in Survivin from 15 mM on
(Figure 8B). However in contrast to wild type cells, no
decline was visible up to 50 mM LiCl, The amount of
Bcl-XL, Bid, Bax and XIAP proteins remained
unchanged (Figure 8A, B; Additional file 6, Figure S6).
Beginning at four hours after LiCl treatment, we also
observed a strong phosphorylation of p42-ERK that
remained high for twenty-four hours and declined
thereafter (Figure 8C).
LiCl induces apoptosis in tumours of syngeneic rats
Induction of apoptosis by inhibition of GSK-3 offers the
possibility of inducing cell death in tumour cells in a
non-genotoxic way. We therefore investigated whether
LiCl reduces tumour growth in vivo. To this end we
employed the rat MT450 syngeneic mammary tumour
model [29]. This cell line is routinely used in tumour
growth and metastasis experiments in vivo in our insti-
tute, and its growth and other characteristics are well
documented. Moreover, the use of a syngeneic animal
model obviates problems associated with the growth of
xenografts in immuno-compromised animals.
Prior to animal experiments, we tested the response of
the MT450 rat mammary tumour cells to LiCl and
alsterpaullone. As shown in Figure 9A, LiCl and alster-
paullone strongly reduced the number of viable MT450
cells in a dose dependent manner as assessed by the
MTT assay (Figure 9A). Likewise, LiCl strongly reduced
the colony forming ability of MT450 cells (Figure 9B).
The reduction in proliferation and colony number was
accompanied by cleavage of PARP and Caspase-3, and
by DNA fragmentation in cell culture experiments (Fig-
ure 9C, D, E), indicating that MT450 cells respond to
LiCl treatment by undergoing apoptosis in a similar
manner to the other cell lines investigated in this study.
To determine whether inhibition of GSK-3b has an
effect on tumour growth in vivo, we implanted MT450
Figure 5 LiCl stimulates the release of a cell death-mediating
factor. (A) U2OS cells were treated with 50 mM LiCl. After 24 hours,
the medium was replaced and cells were incubated for further 8,
16, 24 or 36 hours. Cells were harvested and cell lysates were
prepared (LiCl). The conditioned medium from these cells was
collected after 8, 16, 24 or 36 hours and transferred to untreated
U2OS cells. Thereafter, these cells were incubated for an additional
24 hours. Cell lysates were prepared and 50 μg of protein were
separated on a 15% SDS-PAGE gel. Proteins were transferred onto a
PVDF membrane and probed with an antibody directed against
cleaved Caspase-3, and against PCNA for loading control. (B) U2OS
cells were irradiated with 30 J/m2 UVC. After 24 hours, conditioned
medium was collected and transferred onto fresh U2OS cells. The
cells were harvested ("0”) or incubated for a further 24 hours or 36
hours. Cells that received the conditioned medium were harvested
immediately ("0”) or incubated for further 24 or 36 hours. Cell
lysates were prepared and 50 μg of protein were separated on a
15% SDS-PAGE gel. Proteins were transferred onto a PVDF
membrane and probed with an antibody directed against cleaved
Caspase-3, and against PCNA for loading control.
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Figure 6 LiCl stimulates the release of a TNF-a. (A.I) U2OS cells were cultured in 0.5% FCS and stimulated with 50 mM LiCl. At the indicated
times, the culture medium was harvested and proteins were precipitated using Strataclean Resin. Proteins were eluted with sample buffer and
separated on a 15% SDS-PAGE gel. The gel was silver-stained and photographed. The arrow points to a protein that is only present in LiCl
treated cells. (A.II) The protein that was only present in the cell culture supernatant after treatment of cells with LiCl was eluted from the gel,
digested with trypsin and subjected to MALDI-TOF sequencing. The graph shows the spectrogram from MALDI-TOF sequencing. Arrows point to
peptides characteristic of TNF-a. (A.III) U2OS cells were cultured in 0.5% FCS and stimulated with 50 mM LiCl. After 36 hours, the culture
medium was harvested and proteins were precipitated using Strataclean Resin, eluted with sample buffer and separated on a 15% SDS-PAGE
gel. Proteins were transferred onto a PVDF membrane and probed with antibodies directed against TNF-a. (A.IV) Three Wistar rats were injected
with 50 mg/kg of LiCl or with the vehicle (PBS) for 4 weeks. From 3 weeks after the first drug dose, blood was collected twice a week and TNF-
a levels were determined in the serum using a rat-TNF-a ELISA kit (Invitrogen). Mean values and standard deviations were calculated from three
bleedings and blotted. The value for rats that received the vehicle was set to 1. (B.I) U2OS cells were treated with the indicated concentrations
of LiCl for 24 hours. RNA was prepared and the amount of TNF-a RNA was determined by qRT-PCR. Mean values and standard deviation of 2ΔCT
values of 3 independent experiments were plotted. The data for untreated cells were set to 1. (B.II) U2OS and H1299 cells were treated with 50
mM LiCl and harvested at the indicated time points. RNA was prepared and the amount of TNF-a RNA was determined by qRT-PCR. Mean
values of 2ΔCT values of 2 (H1299) and 3 (U2OS) independent experiments were plotted. The data for untreated cells were set to 1. (C) U2OS
were transfected with siRNA targeted against TNF a or with a control siRNA, or left untransfected for control. 24 hours after transfection, 50 mM
LiCl were added and the cells were incubated for a further 36 hours. Cells were harvested and divided into two aliquots. One of the aliquots
was lysed and 50 μg of protein were separated on a 15% SDS-PAGE gel. Proteins were transferred onto a PVDF membrane and probed with
antibodies directed against cleaved Caspase-3, and against PCNA for a control (C.I). Mean values and standard deviations from three
independent experiments were calculated and plotted. Values for untreated cells were set to 1 (C.II). From the second aliquot, RNA was prepared
and the amount of TNF-a RNA was determined by qRT-PCR. Mean values and standard deviations of 2ΔCT values of the three experiments were
calculated and plotted. The values obtained for TNF-a RNA in the absence of LiCl were set to 1 (C.III). (D) U2OS cells were transfected with
siRNA targeted against TNF-a or with a control siRNA, or left untransfected for control. 24 hours after transfection, 50 mM LiCl were added and
the cells were incubated for a further 36 hours. Relative numbers of viable cells were determined by MTT-assay.
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cells into syngeneic rats and examined the effect of LiCl
on the outgrowth of the ensuing tumours. One week
prior to transplantation of tumour cells, we started to
inject a LiCl solution into a group of eight Wistar Furth
rats once a day. For controls, a similar group of animals
was left untreated. Blood was regularly taken from the
animals and monitored for levels of lithium. When the
serum concentration of lithium reached a concentration
of 0.4 mEq/l, we inoculated 5 × 106 MT450 cells into
each group of rats. Continued daily injections thereafter
with LiCl led to a sustained increase in serum concen-
trations of lithium to over 0.5 mEq/l (Figure 10A.II).
Tumour growth was regularly monitored. In all groups
of animals, tumours developed with 100% penetrance.
However, as can be seen in Figure 10A.I, animals receiv-
ing LiCl injections exhibited a substantial and significant
reduction in tumour growth compared to control ani-
mals. The lithium treatment did not result in any
obvious signs of toxicity in the experimental animals,
such as weight loss or other symptoms associated with
high serum lithium levels.
When tumours in control rats reached a size of about
500 mm3, we sacrificed the animals, and analyzed the
tumours histologically. We stained tumour sections with
an antibody directed against proliferating cell nuclear
antigen (PCNA) and counted PCNA-positive cells to
determine the proliferative capacity of the tumour. In
addition, we performed TUNEL-assays to determine
how many tumour cells underwent apoptosis.
Tumour sections from rats treated with LiCl or non-
treated for control showed an relatively equal number of
PCNA-positive cells (Figure 10B). However, when we
Figure 7 LiCl induces FasL. (A) U2OS cells were treated with the
indicated concentrations of LiCl for 24 hours. RNA was prepared
and the amount of FasL RNA was determined by qRT-PCR. Mean
values and standard deviation of 2ΔCT values of 3 independent
experiments were plotted. The data for untreated cells were set to
1. (B) U2OS and H1299 cells were treated with 50 mM LiCl and
harvested at the indicated time points. RNA was prepared and the
amount of FasL RNA was determined by qRT-PCR. Mean values of
2ΔCT values of 2 (H1299) and 3 (U2OS) independent experiments
were plotted. The data for untreated cells were set to 1. (C) HCT
were transfected with siRNA targeted against TNF-a or with a
control siRNA. 20 hours after transfection, Nok-1 antibody was
added at a dilution of 1:500 where indicated. Four hours later, 50
mM LiCl were added and the cells were incubated for a further 36
hours. Cells were lysed and 50 μg of protein were separated on a
15% SDS-PAGE gel. Proteins were transferred onto a PVDF
membrane and probed with antibodies directed against Caspase-3,
or against PCNA for a control. (D) U2OS cells were transfected with
siRNA targeted against TNF-a or with a control siRNA, or left
untransfected for control. 20 hours after transfection, Nok-1
antibody was added where indicated at a dilution of 1:500. Four
hours later, 25 mM LiCl were added and the cells were incubated
for a further 36 hours. Relative numbers of viable cells were
determined using the MTT-assay.
Figure 8 LiCl increases the amount of Survivin and of
phosphorylated ERK. (A) HCT116 wild type and HCT116 p53-/-
cells were incubated with 50 mM LiCl for the indicated times. Cell
lysates were prepared and 50 μg of protein were separated on a
10% SDS-PAGE gel. Proteins were transferred onto a PVDF
membrane and probed with antibodies directed against Survivin
and Bcl-XL, and against PCNA for a loading control. (B) HCT116 wild
type and HCT116 p53-/- cells were incubated with the indicated
concentrations of LiCl for 48 hours. Cell lysates were prepared and
50 μg of protein were separated on a 10% SDS-PAGE gel. Proteins
were transferred onto a PVDF membrane and probed with
antibodies directed against Survivin and Bcl-XL, and against PCNA
for a loading control. (C) U2OS cells were treated with 50 mM LiCl
and harvested at the indicated time points. Cell extracts were
prepared and 50 μg of protein were separated on a 10% SDS-PAGE
gel. Proteins were transferred onto a PVDF membrane and probed
with an antibody directed against phosphorylated ERK. The
membrane was stripped and reprobed with an antibody directed
against the p42 and p44 kDa forms of ERK, for a loading control.
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stained tumour sections to label apoptotic cells, the
number of TUNEL-positive cells was significantly
increased in sections of tumours derived from LiCl-trea-
ted rats (Figure 10C).
Discussion
In this study, we explored the effect of LiCl on prolifera-
tion and survival of tumour cells. We found that LiCl
induced apoptosis not only in cell culture, but also in
tumour cells in vivo, as demonstrated in syngeneic animal
models treated with non-toxic concentrations of LiCl.
Our experiments demonstrate that LiCl and alster-
paullone, two widely used inhibitors of GSK-3 activity,
are both able to induce apoptosis of tumour cells. These
compounds inhibit GSK-3 by different mechanisms.
Paullones were initially identified as CDK1/CDK2/CDK5
inhibitors using the COMPARE analysis of a data-base
of compounds tested in the National Institute of Health.
A structure/activity relationship study led to the devel-
opment of the more potent CDK inhibitors kenpaullone
and alsterpaullon. These proved to also be excellent
GSK-3 inhibitors and in fact inhibit GSK-3 about ten-
fold more potently than they do CDK1 [30]. Lithium is
a non-competitive inhibitor of GSK-3 and its effect is
reversible in vitro. It potently inhibits GSK-3 (Ki = 2
mM), but is not a general inhibitor of other protein
kinases [7]. Lithium has also been reported to inhibit
inositol-monophosphatase, phospho-monoesterases and
phospho-glucomutase [31-33], but these off-target
effects require higher doses of the compound.
Treatment of cells with lithium inhibits GSK-3-depen-
dent phosphorylation of the microtubule-associated pro-
tein Tau and induces accumulation of cytoplasmic
Armadillo/b-Catenin in PC12 and Drosophila S2 cells,
demonstrating that lithium can mimic Wingless signal-
ling in intact cells [8], consistent with the notion that its
major cellular effect is the inhibition of GSK-3. More-
over, downregulation of GSK-3 also resulted in cleavage
of Caspase-3, supporting the idea that the apoptosis-
inducing activity of LiCl is mediated by inhibiting GSK-
3.
In the presence of the GSK-3 inhibitors, cell prolifera-
tion ceased and apoptosis was induced in all tumour
cell lines that we investigated. Although in certain con-
texts GSK-3 has been found to act as a pro-apoptotic
kinase (reviewed in: [34]), our results clearly show that
tumour cells obviously require GSK-3 activity for cell
survival. In the presence of GSK-3 inhibitors, cells were
positive for all investigated features of apoptosis. Cas-
pase-3 was processed into its active form, PARP was
cleaved and DNA was fragmented into oligonucleo-
somes. At the same time, we did not observe any evi-
dence for induction of senescence or cell death by
autophagy (data not shown). Induction of cell death
after inhibition of GSK-3 has also been observed by
others [35-41].
By what molecular mechanism does LiCl induce apop-
tosis? GSK-3 has numerous cellular targets. For exam-
ple, GSK-3 is well known as an important regulator of
the canonical Wnt pathway (reviewed in: [42]). In unsti-
mulated cells, GSK-3 phosphorylates the N-terminal
domain of b-Catenin, thereby targeting it for ubiquitina-
tion and proteasomal degradation. Exposure of cells to
Wnts leads to inactivation of GSK-3 and correspond-
ingly to the accumulation of b-Catenin. However, this is
unlikely to be involved in LiCl-mediated apoptosis as
enhanced levels of b-Catenin have anti-apoptotic effects
Figure 9 LiCl induces apoptosis in MT450 breast cancer cells.
(A) MT450 rat mammary tumour cells were plated in 96-well plates
at a density of 1 × 103 cells per well. 24 hours after plating, LiCl and
alsterpaullone were added to the indicated concentrations. 72 hours
after drug addition, the relative amount of viable cells was
determined using the MTT-assay. Mean values and standard
deviations of three independent experiments were calculated and
plotted. The relative number of cells in the absence of drug was set
to 100% (D: DMSO control). Statistical analysis was performed for
alterations in relative cell proliferation in comparison to mock-
treated cells (*: P < 0.05; **: P < 0.01). (B) 1 × 103 MT450 cells were
mixed with medium and methylcellulose 4000 containing the
indicated doses of LiCl. After two weeks, the number of colonies
was determined. The graph shows mean values and standard
deviation of three independent experiments. The number of
colonies in the absence of LiCl was set to 1. (C) MT450 cells were
incubated for 36 hours with the indicated doses of LiCl. Cell lysates
were prepared and 50 μg of protein were separated on a 10% SDS-
PAGE gel. Proteins were transferred onto a PVDF membrane and
probed with an antibody directed against PARP, and against PCNA
for a loading control. (D) MT450 cells were incubated with the
indicated doses of LiCl for 36 hours. Cell lysates were prepared and
50 μg of protein were separated on a 15% SDS-PAGE gel. Proteins
were transferred onto a PVDF membrane and probed with an
antibody directed against Caspase-3, or against PCNA for a loading
control. (E) MT450 cells were incubated with 10 or 20 mM LiCl for
24 or 48 hours or left untreated for a control. Fragmented DNA was
isolated and separated on a 1.4% agarose gel.
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(e.g. [43]). Another important protein that is regulated
by GSK-3 is Mdm2. GSK-3 phosphorylates the Mdm2
oncoprotein within its central domain at sites that are
essential for Mdm2-mediated degradation of the p53
tumour suppressor protein. As a consequence, p53
accumulates in the absence of GSK-3 activity, which
allows transcription of its target genes, among which are
a large number of growth arrest- and apoptosis-inducing
candidates [11,22]. However, despite the correlation of
GSK-3 inhibition and p53 activation, we found that p53,
if at all, played only a minor role in the induction of cell
death after treatment of cells with LiCl as cells both
with and without p53 underwent apoptosis in the pre-
sence of LiCl. Moreover, inhibition of p53 by drugs or
downregulation did not reduce Caspase-3 cleavage or
increase cell survival after treatment with LiCl. Never-
theless, cleavage of PARP and Caspase-3 as well as frag-
mentation of DNA was significantly reduced in p53-
deficient HCT116 cells and cell death was initiated
slightly earlier in the p53 positive cells. However, this
may be a characteristic of the individual cell line.
Although the p53-negative cell line HCT116 cell line is
derived from the p53-positive one and should thus have
the same genotype apart from p53, both cell lines may
have acquired alterations later on, which may result in a
different behaviour.
Our results show that a major apoptosis-inducing
mechanism that is induced in both p53-positive and
negative cells by LiCl is the production of TNF-a and
FasL, two death-receptor ligands that activate the extrin-
sic pathway of apoptosis in an autocrine manner, as evi-
denced by activation of Caspase-8. These findings are
consistent with two earlier reports in which TNF-a was
found to be secreted from LiCl-stimulated monocytes
[44,45]. Interestingly, earlier articles reported about a
sensitizing and potentiating role of LiCl for TNF-a-
mediated cytotoxicity [46,47]. We show that LiCl rather
activates the same signalling cascade that TNF-a does
rather than activating a second and complementary
death signalling cascade.
TNF-a and FasL RNAs were strongly induced after
LiCl treatment of both p53-negative H1299 and p53-
positive U2OS cells. Importantly, downregulation of
LiCl-induced TNF-a by siRNA or inhibition of FasL/Fas
interaction by a blocking antibody reduced Caspase-3
cleavage and increased the relative number of viable cells.
Nevertheless, protection from LiCl-induced apoptosis by
siRNA-mediated inhibition of TNF-a expression or treat-
ment with the Nok-1 antibody, even in combination,
never reached 100%. A possible explanation for this
observation might be that the robust induction of TNF-a
and FasL by LiCl was so strong that it was impossible to
suppress it completely by siRNA or antibody treatment.
As shown in Figure 6C.III higher levels of TNF-a are still
present in LiCl-treated cells compared to non-treated
cells, even after transfection of siRNA, which further sup-
ports this notion. Alternatively or in addition, the
observed phosphorylation of ERK, an activator of death-
inducing kinase DAPK as well as other, not investigated
factors, may have contributed to the initiation of apopto-
sis by LiCl after downregulation of TNF-a.
A major finding of this paper is that LiCl not only
reduced cell proliferation in cell culture but also
Figure 10 LiCl reduces tumour growth in syngeneic rats. (A)
Wistar rats were injected with 50 mg/kg of LiCl dissolved in PBS or
received the same amount of PBS without LiCl for control. 14 days
after the first drug dose, 1 × 105 MT450 cells were inoculated
subcutaneously. Tumour sizes and lithium concentrations in the
blood were determined once a week. The graphs show mean
values for 6-8 individuals (A.I) and corresponding blood serum
concentrations of lithium (A.II). (B) Tumours were fixed and sections
were stained for PCNA expression. PCNA-positive cells of an area of
25 mm2 were counted. The graph shows the mean values and
standard deviations of PCNA-positive cells (in%). (C) Tumour
sections were stained for apoptotic cells. TUNEL-positive cells in an
area of 25 mm2 were counted. The graph shows the mean values
and standard deviations of TUNEL-positive cells.
Kaufmann et al. Cell Communication and Signaling 2011, 9:15
http://www.biosignaling.com/content/9/1/15
Page 11 of 16
inhibited tumour growth in syngeneic animal models.
We observed a significant increase in TUNEL-positive
apoptotic cells in tumours from rats that were treated
with LiCl, while we did not see a decrease in the num-
ber of PCNA positive proliferating cells. We therefore
conclude that the reduction in tumour size in LiCl-trea-
ted animals is due to the induction of apoptosis. The
steady-state level of lithium that we achieved in the ani-
mals is in the range of the concentration that is well tol-
erated by humans [48]. Additionally, we did not observe
any loss in weight of the rats or other evidence of toxic
effects. Moreover, we observed inhibition of cell prolif-
eration and induction of apoptosis in cell culture experi-
ments using significantly lower concentrations of
lithium than those achieved in the animal experiments.
Together these observations suggest that our experimen-
tal tumour data should be highly relevant and applicable
to human cancer therapy.
Our data have several important implications regard-
ing cancer therapy. Induction of cell death by GSK-3
was largely independent of p53, although the presence
of p53 slightly enhanced the cell death-inducing activ-
ity of LiCl, particularly at low doses. Nevertheless, it
should be noted that sequencing of the p53 gene in
the MT450 breast tumour cell line revealed a mutation
at position 174 within a hot spot of inactivating muta-
tions, where tryptophan was replaced with a cysteine
(data not shown). The positive response of the
tumours in the rat to LiCl therefore further supports
the p53-independence of apoptosis induction by LiCl.
Considering that about 50% of tumours possess muta-
tions in the p53 gene, inhibition of GSK-3 would
therefore also be suitable for the treatment of p53-
negative and -mutant tumours that are refractory to
other types of treatment. However, it should be noted
that two previous studies observed a strong p53-
dependency for the inhibition of tumours in mice by
inhibitors of GSK-3 [40,41]. The reason for this discre-
pancy is probably that while we treated the cells with
LiCl, the other studies employed Purvalanol A and
LY2119301 to inhibit GSK-3 [40,41]. It is possible that
these compounds have off-target effects that induce
p53-dependent apoptosis more potently than their
effects on GSK-3 activity. This notion is supported by
the fact that these authors report activation of Bax and
release of cytochrome C [40] which we did not
observe. On the other hand, it cannot be entirely
excluded that LiCl may have some GSK-3-independent
death-inducing activities. Inhibition of GSK-3 by
lithium is a well-established therapy that has been
used for many years for the treatment of mental disor-
ders. Our data indicate that inhibition of GSK-3 activ-
ity deserves to be investigated further as a potential
anti-cancer treatment.
Conclusions
LiCl induced cell death in p53-replete and p53-deficient
cells. Thus, induction of cell death by LiCl does not
require the presence of wild type p53, although we can-
not completely rule out the possibility that LiCl may
activate two or more death pathways, one of which may
involve p53 while the other(s) may not. Induction of cell
death strongly depended on the inhibition of GSK-3 and
on the production of TNF-a and FasL, which are
released into the culture medium after treatment of cells
with LiCl and which mediated cleavage of Caspases-3
-8 and -10.
Methods
Cell culture
U2OS cells, H1299 cells and HCT116 cells (wild type
and p53-/-) were obtained from G. Taucher-Scholz (GSI,
Darmstadt). Mouse embryonic fibroblasts (MEF; wild
type and p53-/-) were provided by Bernd Kaina (Univer-
sity of Mainz) and RKO cells by Martin Scheffner (Uni-
versity of Konstanz). HaCat, Hela tk- and MT450 cells
have been described previously [29,49,50]. All cell lines
were cultured in DMEM supplemented with 10% FCS
and 1% Penicillin/Streptomycin and incubated at 37°C
and 5% CO2 in a humidified atmosphere.
Cell numbers were evaluated with an improved Neu-
bauer chamber and a light microscope. To determine
the number of dead cells, the cell suspension was mixed
1:1 with 1% trypan blue in PBS immediately prior to
microscopy. LiCl was obtained from Sigma, alsterpaul-
lone from Calbiochem, pifithrin-a and pifithrin-μ were
purchased from Merck and TNF-a from Enzo Life
Sciences.
For UV-irradiation, culture medium was removed and
cells were washed once with PBS. After irradiation with
30 J/m2 with a UVC lamp, the initial culture medium
was added back and the cells were further incubated.
Animal experiments
Young adult Wistar Furth rats weighing 200-250 g were
kept on a 12 h light/dark cycle and fed ad libitum. Once
a day, 50 mg/kg LiCl dissolved in PBS was injected i.p.
Control animals received the same amount of PBS with-
out LiCl. Two weeks after the first injection of LiCl, 5 ×
106 MT460 cells in a total volume of 100 μl were inocu-
lated subcutaneously. Tumour size was determined
twice a week with a calliper. Blood samples were taken
once a week six hours after LiCl treatment. Lithium
concentration was determined by flame photometry by a
commercial service provider (Laborgemeinschaft Albtal,
Ettlingen, Germany)
For determining TNF-a serum levels, young adult
Wistar Furth rats weighing 200-250 g were kept on a
12 h light/dark cycle and fed ad libitum. Once a day,
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50 mg/kg LiCl dissolved in PBS was injected i.p. Control
animals received the same amount of PBS without LiCl.
Three weeks after the first injection of LiCl, blood sam-
ples were taken twice a week. TNF-a was determined in
serum with a rat-TNF-a ELISA kit (Invitrogen) accord-
ing to the manufacturer’s recommendation.
The animal studies were approved by the local regula-
tory authority (Regierungspräsidium Karlsruhe). Permis-
sion #35-9185.81/G-83/04.
Antibodies
Anti-PCNA antibodies were obtained from Dako
(Immunohistochemistry) and from Santa Cruz (Western
blotting). The anti-p53 antibodies DO-1 and Ab-2 were
purchased from Santa Cruz and Merck, respectively.
The anti-Bcl-XL, anti-Bax, anti-Caspase-3, anti-cleaved
Caspase-8, anti-Caspase-8, anti-Survivin, anti-XIAP,
anti-ERK and anti-GSK-3b antibodies were from Cell
Signalling. The anti-GSK-3a anti-PARP, anti-Bid and
anti-phosphorylated-ERK (p42 kDa) antibodies were
from Santa Cruz. The anti-Caspase-10 antibody was
purchased from MBL and the anti-cytochrome C and
anti-FasL (Nok-1) antibodies were from BD Biosciences.
HRP-coupled secondary antibodies were purchased from
Dako.
siRNA
siRNA targeted against GSK-3a (5’-CAUUCUCAUCC-
CUCCUCACUU-3’), GSK-3b (5’-GAGCAAAUCAGA-
GAAAUGAAC-3’), TNF-a (5’-GUGCUGGCAACCA
CUAAGA-3’;) or p53 (AACCACUGGAUGGAGAAUA)
or control siRNA (CCCCUUUUAAAAGGGGCCC) was
transfected into U2OS or HCT116 cells using Lipofecta-
min (Invitrogen) to a final concentration of 50 pMol/ml
according to the manufacturer’s recommendations.
Soft agar assay
1 × 103 MT450 cells were mixed with 1.5 ml DMEM
medium supplemented with 10% FCS, 1% Penicillin/
Streptomycin and 0.5 ml of a 1.2% solution of methyl-
cellulose 4000 in DMEM. After two weeks, the number
of colonies was determined with a light microscope.
Colony assay
200 cells were plated per 5 cm-dish and cultured for
two weeks in the presence or absence of LiCl. The cul-
ture medium was removed and cells were washed twice
in ice cold PBS. Cells were fixed in methanol for 5 min,
stained with 0.5% crystal violet in PBS and counted.
MTT assay
2 × 104 cells per well were plated into a 96-well plate.
24 hours after plating, cells were stimulated with LiCl or
alsterpaullone and cultured for an additional 3 days.
Mock-treated controls were treated similarly. MTT was
dissolved at a concentration of 1 mg/ml in DMEM sup-
plemented with 10% FCS and 1% Penicillin/Streptomy-
cin and added at a final concentration of 0.5 mg/ml for
4 hours. The medium was aspirated and 100 μl isopro-
panol were added. Formazan conversion was determined
at 595 nm using an ELISA reader.
Western blotting
Western blotting was performed as described previously
[51]. To determine the release of cytochrome C, 5 × 106
cells were harvested, washed twice with ice-cold PBS
and resuspended in 5 volumes of buffer A (150 mM
sucrose, 20 mM HEPES pH 7.5, 1.5 mM MgCl2, 10 mM
KCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.1 mM
PMSF, 10 μg/ml leupeptin and 10 μg/ml aprotonin) and
incubated for 20 min on ice. The lysate was cleared by
centrifugation at 14 000 rpm for 15 minutes at 4°C. Mito-
chondria were pelleted by centrifugation at 100 000 rpm
in a Sorvall Discovery ultracentrifuge for 1 hour at 4°C.
50 μg of the supernatant were mixed with an equal
volume of 2 × sample buffer [51], heat denatured and
loaded onto an SDS-PAGE gel.
TUNEL assay and immunohistochemistry
Tumours were fixed overnight in formalin (3.7% formalde-
hyde in PBS), and stored in 50% ethanol until they were
embedded in paraffin. Tumour sections were stained for
apoptotic cells using the Apoptag kit (Chemicon) accord-
ing to the manufacturer’s recommendation. For PCNA
staining, sections were deparaffinised, then incubated for
10 minutes in 2 M HCl and washed 4 times with H2O.
Subsequently, sections were immersed in methanol/0.3%
H2O2 for 20 minutes, washed 3 times with PBS, and then
blocked for 15 minutes in PBS/10% rabbit serum. PCNA
antibodies were diluted in PBS/10% rabbit serum to a final
concentration of 10 μg/ml and incubated with the sections
overnight at 4°C. The sections were washed 3 times with
PBS and immersed in 3% H2O2 in PBS for 5 minutes. A
biotinylated rabbit anti-mouse antibody, diluted 1:400 in
PBS/10% FCS was applied to the sections and incubated
for 30 minutes at room temperature. Sections were
washed 3 times with PBS and incubated for 30 minutes
with a StreptABComplex/HRP (Dako) solution, prepared
according to the manufacturer’s recommendations. Sec-
tions were washed 3 times with PBS, incubated with an
AEC-one-component-solution (Innovative Diagnostic-
Systems) for 10 min and counterstained with haematoxylin.
Caspase-8 activity assay
Caspase-8 activity assay was performed according to the
manufacturer’s instructions (Clontech).
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FACS-analysis
For cell cycle analysis, cells were treated with 50 mM
LiCl for 16, 24 and 36 hours, harvested, mixed with ice-
cold 70% ethanol and fixed overnight at 4°C. Cells were
pelleted at 530 g for 5 minutes, washed once with PBS
and stained with Draq5 (Biostatus Ltd) at a final con-
centration of 10 μM for 15 minutes in the dark. DNA
content of the cells was determined using a flow cyt-
ometer (FACScan; Becton Dickinson).
For assessing apoptosis/necrosis, cells were treated
with 50 mM LiCl for 16, 24 and 36 hours, trypsinized,
washed with PBS and resuspended in 400 μl Ca2+-bind-
ing buffer (10 mM HEPES pH 7.6, 140 mM NaCl,
5 mM CaCl2). Subsequently 1 μl of a 1 mg/ml propi-
dium iodide solution (staining late apoptotic and necro-
tic cells) and 5 μl of FITC-coupled AnnexinV (BD
Bioscience; to detect early apoptosis) were added to the
cells. After incubation on ice for 10 min, cells were ana-
lyzed flow cytometrically (FACScan; Becton Dickinson).
Determination of apoptosis by DNA fragmentation and
Cell Death ELISA
For determining apoptosis by assessing DNA fragmenta-
tion, cells were lysed in 125 μl buffer A (20 mM EDTA,
50 mM Tris pH7.5, 1%NP40; pH7) for 1.5 min on ice and
samples were centrifuged at 4500 rpm for 5 min. 10 μl of
a 10% SDS-solution and 20 μl RNAse A (20 mg/ml) were
added to the supernatant and incubated for 2 h at 56°C.
Then 25 μl Proteinase K (10 mg/ml) were added and
samples were incubated for 2 h at 37°C. 50 μl of ammo-
nium acetate (10 M) and 500 μl EtOH were added, and
the DNA was precipitated over night at -20°C before the
DNA was analysed by agarose gel electrophoresis.
Induction of apoptosis and necrosis was furthermore
determined using the Cell Death ELISA-Plus kit
(Roche). The assay was performed according to the
manufacturer’s recommendations.
Extraction of proteins with StrataClean Resin
5 μl of resin were washed with PBS and incubated with
5 ml of cell culture supernatant for 1 hour at room tem-
perature. The resin was washed twice with PBS and
bound proteins were eluted by boiling in 1 × sample
buffer for 5 min at 95°C.
Silver staining and MALDI-TOF Sequencing
The gel was fixed in 40% EtOH and 6% acetic acid for
30 min. Afterwards the gel was incubated in solution A
(30% EtOH; 5% sodium thiosulfate; 6.8% sodium acet-
ate) and washed 3 times for 5 min with H2O. The gel
was then incubated in solution B (0.25% silver nitrate;
0.015% formaldehyde) for 20 min and washed twice for
1 min with H2O. The staining was developed in solution
C (2.5% sodium carbonate; 0.0075% formaldehyde) and
the reaction was stopped by gently shaking the gel in an
EDTA solution (1.46% EDTA in H2O) for 10 min.
The protein of interest was cut out from the gel and
destained twice for 10 min each in washing solution
(10 mM K4Fe(CN)6, 66 mM S2O3). The gel piece was then
washed for 10 min in 10 mM NH4HCO3 and incubated for
10 min in ACN solution (50% ACN, 5 mM NH4HCO3. To
reduce disulfide bonds in the proteins, the gel piece was
incubated for 15 min at 60°C in 10 mM DTT. Unreacted
DTT was removed and free cysteine residues were alkylated
by incubation of the gel pieces with IAA solution (0.1%
iodacetamid in 10 mM NH4HCO3). The gel piece was
washed 6 times for 10 min in NH4HCO3 and dried. Tryp-
sin solution (100 ng/μl trypsin in 10 mM NH4HCO3) was
added to the dried gel piece, overlaid with 10 mM
NH4HCO3 and incubated overnight at RT with constant
shaking. The digest was stopped by the addition of 0.1%
TFA. Protein fragments were eluted by centrifugation and
analysed by MALDI-TOF.
RT-PCR
Total RNA was prepared from cells using the RNeasy
kit (Qiagen) according to the manufacturer’s instruc-
tions and treated with DNase I to remove residual geno-
mic DNA. RNA was transcribed into cDNA using
random primers and RevertAid™ H MinusM-MuLV
reverse transcriptase (Fermentas). The quality of cDNA
was tested by conventional PCR and actin primers. Real-
time PCR was performed in duplicates with a SYBR
Green PCR mixture (Qiagen). The cDNA was denatured
for 4 min at 90°C followed by 40 cycles of 90°C for 30 s,
60°C for 45 sec and 72°C for 45 sec and a final exten-
sion step of 5 min at 72°C using the Step-One-Plus
sequence detection system (Applied Biosystems) and
gene specific primers. The signals were normalized to
the signals for the ribosomal subunit 36B4. Sequences of
primers are available on request.
Statistical analysis
Differences between treated and mock-treated controls
were examined using the unpaired students T-Test. P
values < 0.05 were considered to be statistically signifi-
cant. All of the statistical tests were performed with
Microsoft Office Excel 2010 software.
Additional material
Additional file 1: Figure S1 - p53 status of cell lines. HCT116 wild
type and HCT116 p53-/-, mouse embryonic fibroblasts (MEF) wild type
and MEF p53-/-, SaOs-2 and U2OS cells were lysed. 50 μg of protein were
separated on a 10% SDS-PAGE gel and transferred onto a PVDF
membrane. The membrane was probed with an antibody directed
against p53, and against PCNA for loading control.
Additional file 2: figure S2 - The reduction in proliferation and
colony forming ability in response to LiCl is independent of p53.
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(A) U2OS and HCT116 wild type cells were plated in 96-well plates at a
density of 1 × 103 cells per well. 20 hours after plating, pifithrin-a or the
vehicle (DMSO) were added to the cells at a final concentration of 50
μM. After additional 4 hours, LiCl was added at the indicated
concentrations. 72 hours after drug addition, the relative number of
viable cells was determined by MTT-assay. Mean values and standard
deviations of three independent experiments were calculated and
plotted. The relative number of cells in the absence of drug was set to
100%. (B) U2OS cells were transfected with siRNA targeted against p53
or with a control siRNA. 24 hours after transfection LiCl was added at the
indicated concentrations. 72 hours after drug addition, the relative
number of viable cells was determined by MTT-assay. Mean values and
standard deviations of three independent experiments were calculated
and plotted. The relative number of cells in the absence of drug was set
to 100%. (C) 200 p53-positive (wild type) and p53-negative HCT116
(HCT116 p53-/-) cells were plated in 5 cm dishes. LiCl was added at the
indicated doses. Two weeks after plating, colonies were stained with
crystal violet and counted. The graph shows mean values and standard
deviations of 3 independent experiments. Relative numbers of colonies
of mock-treated cells were set to 100%.
Additional file 3: Figure S3 - PARP and Caspases are cleaved after
treatment with LiCl. (A) HCT116 wild type and HCT116 p53-/- cells were
incubated with the indicated doses of LiCl for 48 hours. Cell lysates were
prepared and 50 μg of protein were separated on a 10% SDS-PAGE gel.
Proteins were transferred onto a PVDF membrane and probed with an
antibody directed against PARP, Caspase-3 and Caspase-10, or against
PCNA for a loading control. (B) HCT116 wild type cells were incubated
with 50 μM pifithrin-a, 10 μM pifithrin-μ, with both, or with vehicle
(DMSO) for control. After 4 hours, 50 mM LiCl were added. 36 hours after
the addition of LiCl, cell lysates were prepared and 50 μg of protein
were separated on a 15% SDS-PAGE gel. Proteins were transferred onto a
PVDF membrane and probed with an antibody directed against Caspase-
3, or against PCNA for loading control. (C) U2OS cells were transfected
with siRNA targeted against p53 or with a control siRNA. 24 hours after
transfection 50 mM LiCl were added. 36 hours after the addition of LiCl,
cell lysates were prepared and 50 μg of protein were separated on a
15% SDS-PAGE gel. Proteins were transferred onto a PVDF membrane
and probed with an antibody directed against Caspase-3, or against
PCNA for a loading control.
Additional file 4: Figure S4 - LiCl does not induce the release of
Cytochrome C from mitochondria. HCT116 wild type and HCT116
p53-/- cells were incubated with 50 mM LiCl for the indicated time. Cells
were lysed and mitochondria were separated from the cytoplasmic
fraction by centrifugation. 50 μg of protein of the cytoplasmic fraction
were separated on a 15% SDS-PAGE gel, transferred onto a PVDF
membrane and probed with an antibody directed against cytochrome C,
or PCNA for a loading control.
Additional file 5: Figure S5 - Caspase 3 cleavage and cell survival in
dependence of TNF-a and FasL. (A) U2OS and HCT116 wild type cells
were plated in 96-well plates at a density of 1 × 103 cells per well. 24
hours after plating, TNF-a was added to the indicated concentrations. 72
hours after drug addition, the relative number of viable cells was
determined by MTT-assay. Mean values and standard deviations of three
independent experiments were calculated and plotted. The relative
number of cells in the absence of TNF-a was set to 100%. (B) HCT116
wild type cells were transfected with siRNA targeted against TNF-a or
with a control siRNA, or left untransfected for control. 24 hours after
transfection, 25 mM LiCl were added and the cells were incubated for
further 36 hours. Cells were lysed and 50 μg of protein were separated
on a 15% SDS-PAGE gel. Proteins were transferred onto a PVDF
membrane and probed with antibodies directed against cleaved
Caspase-3, or PCNA for a control. (C) U2OS were transfected with siRNA
targeted against TNF-a or with a control siRNA. 20 hours after
transfection, Nok-1 antibody was added at a dilution of 1:500 where
indicated. Four hours later, 50 mM LiCl were added and the cells were
incubated for a further 36 hours. Cells were lysed and 50 μg of protein
were separated on a 15% SDS-PAGE gel. Proteins were transferred onto a
PVDF membrane and probed with antibodies directed against Caspase-3,
or PCNA for a control.
Additional file 6: Figure S6 - S6: Treatment with LiCl does not affect
expression of Bax, XIAP or Bid. (A) HCT116 wild type and HCT116
p53-/- cells were incubated with the indicated doses of LiCl for 48 hours.
Cell lysates were prepared and 50 μg of protein were separated on a
10% SDS-PAGE gel. Proteins were transferred onto a PVDF membrane
and probed with antibodies directed against Bax, XIAP and Bid, or
against PCNA for a loading control. (B) HCT116 wild type and HCT116
p53-/- cells were incubated with 50 mM LiCl for the indicated times. Cell
lysates were prepared and 50 μg of protein were separated on a 10%
SDS-PAGE gel. Proteins were transferred onto a PVDF membrane and
probed with antibodies directed against Bax, XIAP and Bid, or against
PCNA for a loading control.
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